Hawaii Secures $916 Million in Plavix Lawsuit Against Bristol-Myers and Sanofi

Hawaii Secures $916 Million in Plavix Lawsuit Against Bristol-Myers and Sanofi

A Hawaii court has ordered pharmaceutical companies Bristol-Myers Squibb and three U.S.-based subsidiaries of Sanofi to pay the state $916 million in a lawsuit regarding the marketing of the blood thinner Plavix. The lawsuit, led by Attorney General Anne Lopez, accused the companies of violating state laws against unfair and deceptive practices by failing to disclose the efficacy and safety profiles of the drug. The court found that the companies' actions were deliberate and negatively affected scientific development related to Plavix, particularly impacting patients of East Asian and Pacific Island descent.

The judgement follows allegations that the drug was less effective in individuals with certain liver-enzyme mutations common among these populations, posing significant health risks. The state plans to use the awarded funds to improve healthcare delivery in Hawaii. Both Bristol-Myers Squibb and Sanofi have stated their disagreement with the ruling and intend to appeal, calling the penalties "unwarranted and out of proportion." This case, originally filed in 2014, had previously seen an $834 million judgment, which was later increased. The U.S. Food and Drug Administration had issued a warning label in 2010 to reflect the drug's limitations.

Summary

Other news in health